The SURPASS-5 (Study of Tirzepatide in Participants With Type 2 Diabetes on Insulin Glargine) trial demonstrated that switching to tirzepatide from insulin therapy significantly reduced insulin requirements [7]. Here, INS is linked to type 2 diabetes mellitus.